DRG Market Assessment reports

The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which…

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…

The treatment of ovarian cancer has been transformed by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (Zejula; GSK), and…

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs or systems in the body. The treatment goals of physicians who manage SLE patients differ depending on…

The urticaria drug market is dominated by oral medications—including steroids and second-generation, nondrowsy antihistamines—which are prescribed for both chronic inducible urticaria (CIndU)…

The advent of Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) has revolutionized the treatment of gastroesophageal cancer, leading to substantial growth of this…

The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication:…

Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…

Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has been the mainstay AML treatment for a long time, the recent…

Heart failure (HF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (AHF) and…

Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. However,…

The launch of several novel therapies, as well as multiple label expansions of existing drugs, will fuel significant growth of the NHL therapy market in China over the next 10 years. Rituximab (…